Latest news

• EU approves Alexza’s antipsychotic Adasuve

  Company plans to launch it in third quarter of 2013 in partnership with Grupo Ferrer

• FDA panel backs Alexza’s inhaled antipsychotic drug

  Shares in Alexza climbed more than 70 per cent after the 9-8 vote by the Psychopharmacologic Drugs Advisory Committee (PDAC) improved the chances that Adasuve (loxapine delivered using Alexza's ... The speed of onset of treatment with inhaled loxapine is

• Schizophrenia treatments

  The product uses the Alexza's Staccato hand-held, disposable inhaler technology which vaporises loxapine by heating a thin film of the agent. . ... Worldwide revenue projections for inhaled loxapine, cariprazine and TC 5619 are represented in figure

• Alexza schizophrenia drug delayed

  Alexza said it had completed an end-of-review meeting with the FDA for Adusuve Staccato (loxapine) inhalation aerosol, which is being developed for the rapid treatment of agitation in schizophrenia

• Alexza psychiatric drug delayed

  Alexza Pharmaceuticals has received a Complete Response Letter (CRL)  from the US Food and Drug Administration (FDA) voicing concerns about the safety of Adusuve Staccato (loxapine) inhalation aerosol.